 | |
| Clinical data | |
|---|---|
| Other names | N-Desethyl-N-methyltiletamine |
| Drug class | Dissociative;Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C11H15NOS |
| Molar mass | 209.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tilmetamine is adissociativedrug of thearylcyclohexylamine family related totiletamine.[1][2] It is theanalogue of tiletamine in which theN-ethyl group has been replaced with anN-methyl group.[1][2] The drug is said to be 3 to 5 times morepotent thanketamine and to have a longerduration.[1][2] It is reported to produceadverse effects, such asblurred vision.[1][2] Tilmetamine is expected to act as anNMDA receptor antagonist similarly to tiletamine and ketamine.[1][2] It was encountered as a noveldesigner drug online in August 2024.[1][2]
 | Thishallucinogen-related article is astub. You can help Wikipedia byadding missing information. |